Elevated levels of APOA1 correlate with a decrease in inflammatory markers, potentially slowing HCC progression by modulating the activation of immune cells, including macrophages and T cells, while also reducing cytokine production [42]. This evidence concerns the gene APOA1 and hepatocellular carcinoma.